Results 181 to 190 of about 3,679,356 (272)

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study. [PDF]

Blood Cancer J
Wurm S, Moritz JM, Petzer V, Wolf D, Gleixner KV, Sperr WR, Groiss C, Machherndl-Spandl S, Eisenwort G, Koller E, Schoeche J, Petrasch C, Singer J, Mayer DM, Pregartner G, Heine A, Wölfler A, Sill H, Reinisch A, Zebisch A.   +19 more
europepmc   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +1 more source

Ivosidenib or venetoclax combined with hypomethylating agents in <i>IDH1</i>-mutated acute myeloid leukemia: a real-world study. [PDF]

Blood Neoplasia
Lachowiez CA, Smith BD, Ambinder AJ, Binder G, Angiolillo A, Potluri R, Papademetriou E, LeBlanc TW.   +7 more
europepmc   +1 more source

Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes. [PDF]

Ann Hematol
Sanz-Solas A, Saiz-Rodríguez M, Simal SC, Rodríguez-Veiga R, Solana-Altabella A, Montesinos P, Labrador J.   +6 more
europepmc   +1 more source

The Effectiveness of Hypomethylating Agents in Elderly Patients With Acute Myeloid Leukemia: Insights From a Single-Center Experience. [PDF]

Cureus
Negotei C, Mitu I, Stanca O, Angelescu S, Lapadat ME, Barta C, Berbec NM, Colita A.   +7 more
europepmc   +1 more source

Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]

Ann Hematol
Lee BJ.
europepmc   +1 more source

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia. [PDF]

Cancer Med
Cai Y, Rui J, Ding Z, Xie J, Jin Z, Xiao J, Xu Y.   +6 more
europepmc   +1 more source

Latest update in the management of pancreatic cancer [PDF]

, 2008
Yau, TCC
core  

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents. [PDF]

Am J Hematol
Marconi G, Petracci E, Lanzarone G, Vetro C, Martelli MP, Papayannidis C, Audisio E, Minetto P, Riva C, Guolo F, Martini G, Zappasodi P, Vincenzo F, Gigli F, Griguolo D, Rondoni M, Ciotti G, Borlenghi E, Ciccone N, Palumbo FE, Nanni J, Mattei D, Bernardi M, Cignetti A, Zingaretti C, Vertogen B, Cerchione C, Lanza F, Cilloni D, Brunetti L, Palmieri R, Curti A, Giannini MB, Todisco E, AVALON research group, Fracchiolla N, Martinelli G.   +36 more
europepmc   +1 more source

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study. [PDF]

Exp Hematol Oncol
Zugasti I, Lopez-Guerra M, Castaño-Díez S, Esteban D, Avendaño A, Pomares H, Perez A, García-Ávila S, Conejo IP, de la Fuente Montes C, Martínez-Roca A, Merchán B, Jiménez-Vicente C, Guijarro F, Álamo JR, Cortes-Bullich A, Torrecillas V, Mont L, Carcelero E, Riu G, Zamora L, Bargay J, Triguero A, Suarez-Lledó M, Salas MQ, López-Cadenas F, Ramos F, Xicoy B, Valcárcel D, Arnan M, Martínez C, Rovira M, Fernández-Avilés F, Díez-Campelo M, Esteve J, Díaz-Beyá M.   +35 more
europepmc   +1 more source